PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

Patients with metastatic cancer refractory to standard systemic therapies have a poor prognosis and few therapeutic options. Radiotherapy can shape the tumor microenvironment (TME) by inducing immunogenic cell death and promoting tumor recognition by natural killer cells and T lymphocytes. Granulocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Yuehong, Zhao, Xiangrong, Xu, Meiling, Pan, Jie, Ma, Yifu, Zou, Li, Peng, Qiliang, Zhang, Junjun, Su, Cunjin, Xu, Zhi, Zhou, Wei, Peng, Yong, Yang, Jiabao, Zhou, Chengliang, Li, Yujia, Guo, Qiuchen, Chen, Guangqiang, Wu, Hongya, Xing, Pengfei, Zhang, Liyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304897/
https://www.ncbi.nlm.nih.gov/pubmed/35874780
http://dx.doi.org/10.3389/fimmu.2022.952066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304897/
https://www.ncbi.nlm.nih.gov/pubmed/35874780
http://dx.doi.org/10.3389/fimmu.2022.952066

Ejemplares similares